Compare PGC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGC | ADCT |
|---|---|---|
| Founded | 1921 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.9M | 496.7M |
| IPO Year | N/A | 2020 |
| Metric | PGC | ADCT |
|---|---|---|
| Price | $29.70 | $4.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $35.33 | $7.60 |
| AVG Volume (30 Days) | 174.9K | ★ 1.6M |
| Earning Date | 01-27-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 6.12 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $248,809,000.00 | $75,209,000.00 |
| Revenue This Year | $27.34 | $10.36 |
| Revenue Next Year | $16.59 | $3.87 |
| P/E Ratio | $15.37 | ★ N/A |
| Revenue Growth | ★ 18.63 | 6.35 |
| 52 Week Low | $23.96 | $1.05 |
| 52 Week High | $36.27 | $4.80 |
| Indicator | PGC | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 71.44 | 49.48 |
| Support Level | $27.80 | $3.15 |
| Resistance Level | $28.34 | $4.32 |
| Average True Range (ATR) | 0.63 | 0.39 |
| MACD | 0.27 | 0.03 |
| Stochastic Oscillator | 91.93 | 62.40 |
Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Wealth Management Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and Internet banking services. Wealth Management includes investment management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services. The services provided by the company include checking and savings accounts, money market and interest-bearing checking accounts, certificates of deposit, individual retirement accounts, and other services.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).